Mouse models of tuberous sclerosis complex

Journal of Child Neurology

Volumn 19, Issue 9, 2004, Pages 726-733

  Scheidenhelm, Danielle K ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; TUBERIN;

ANIMAL MODEL; AUTISM; BRAIN INJURY; BRAIN TUMOR; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; EPILEPSY; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; GLIOMA; KNOCKOUT MOUSE; MENTAL DEFICIENCY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

EID: 8844279090     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738040190091401     Document Type: Review

References (77)

1. Gomez MR, Sampson JR, Whittemore VH: Tuberous Sclerosis 3rd ed. New York, Oxford University Press, 1999.
2. Asano E, Chugani DC, Muzik O, et al: Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology 2001;51:1269-1277.
3. Bolton PF, Park RJ, Higgins NP, et al: Neuro-epileptic determinants of autisum spectrum disorders in tuberous sclerosis complex. Brain 2002;125:1247-1255.
4. Bolton PF, Griffiths PD: Association of tuberous sclerosis of temporal lobes with autism and atypical autism. Lancet 1997; 349:392-395.
5. Shepard CW, Houser OW, Gomez MR: MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. AJNR Am J Neuroradiol 1995;16:149-155.
6. Joinson C, O'Callaghan FJ, Osborne JP, et al: Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003;33:335-344.
7. Curatolo P, Seri S, Verdecchia M, Bombardieri R: Infantile spasms in tuberous sclerosis complex. Brain Dev 2001;23:502-507.
8. Curatolo P: Neurological manifestation of tuberous sclerosis complex. Childs Nerv Syst 1996;12:515-521.
9. Cusmai R, Chiron C, Curatolo P, et al: Topographic comparative study of MRI and EEG in 34 children with tuberous sclerosis. Epilepsia 1990;31:747-755.
10. Goodman M, Lamm SH, Engel A, et al: Cortical tuber count: A biomarker indicating neurologic severity of tuberous sclerosis complex. J Child Neurol 1997;12:85-90.
11. Hancock E, Osborne JP: Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: Literature review. J Child Neurol 1999;41:123-126.
12. Bebin EM, Kelly PJ, Gomez MR: Surgical treatment for epilepsy in cerebral tuberous sclerosis. Epilepsia 1993;34:651-657.
13. Park SH, Pepkowitz SH, Kerfoot C, et al: Tuberous sclerosis in a 20-week gestation fetus: Immunohistochemical study. Acta Neuropathol (Berl) 1997;94:180-186.
14. Crino PB, Dichter MA, Trojanowski JQ, Eberwine J: Embryonic neuronal markers in tuberous sclerosis: Single cell molecular pathology. Proc Natl Acad Sci U S A 1995;93:14152-14157.
15. Yamanouchi H, Jay V, Rutka JT, et al: Evidence of abnormal differentiation in giant cells of tuberous sclerosis. Pediatr Neurol 1997;17:49-53.
16. Lee A, Maldonado M, Baybis M, et al: Markers of cellular proliferation are expressed in cortical tubers. Ann Neurol 2003; 53: 668-673.
17. Mizuguchi M, Takashima S: Neuropathology of tuberous sclerosis. Brain Dev 2001;23:508-515.
18. Shepard CW, Scheithauer BW, Gomez MR, et al: Subependymal giant cell astrocytoma: A clinical, pathologic, and flow cytometry study. Neurosurgery 1991;38:864-869.
19. Mirkin LD, Ey EH, Chaparro M: Congenital subependymal giant cell astrocytoma: Case report with prenatal ultrasonogram. Pediatr Radiol 1999;29:776-780.
20. Povey S, Burley MW, Attwood J, et al: Two loci for tuberous sclerosis: One on 9q34 and one on 16p13. Ann Hum Genet 1994; 58:107-127.
21. van Slegtenhorst M, de Hoogt R, Hermans C, et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-808.
22. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-1315.
23. van Slegtenhorst M, Nellist M, Nagelkerken B, et al: Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998;7:1053-1057.
24. Plank TL, Yeung RS, Henske EP: Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998;58:4766-4770.
25. Hodges AK, Li S, Maynard J, et al: Pathologic mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet 2001;159:217-224.
26. Kwiatkowski DJ: Tuberous sclerosis: From tubers to mTOR. Ann Hum Genet 2003;67:87-96.
27. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ: Molecular genetic advances in tuberous sclerosis. Hum Genet 2000;107: 1135-1138.
28. Henske EP, Scheithauer BW, Short MP, et al: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996;59:400-406.
29. Niida Y, Stemmer-Rahamimov AO, Logrip M, et al: Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001;69:493-503.
30. Benvenuto G, Li S, Brown SJ, et al: The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000;19:6306-6316.
31. Miloloza A, Rosner M, Nellist M, et al: The TSC1 gene product, hamartin, negatively regulates cell proliferation. Hum Mol Genet 2000;9:1721-1727.
32. Soucek T, Yeung RS, Hengstschlager M: Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci U S A 1998;95:15653-15658.
33. Soucek T, Pusch O, Wienecke R, et al: Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces cells to enter S phase. J Biol Chem 1997;272:29301-29308.
34. Mizuguchi M, Kato M, Yamanouchi H, et al: Tuberin immunohistochemistry in brain, kidneys, and heart with or without tuberous sclerosis. Acta Neuropathol (Berl) 1997;94:525-531.
35. Gutmann DH, Zhang Y, Hasbani MJ, et al: Expression of the tuberous sclerosis complex gene products, hamartin and tubenin, in central nervous system tissues. Acta Neuropathol (Berl) 2000;5:276-286.
36. Soucek T, Holzl G, Bernaschek G, Hengtschlager M: A role of the tuberous sclerosis gene-2 product during neuronal differentiation. Oncogene 1998;16:2197-2204.
37. Wienecke R, Guha A, Maize JC, et al: Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol 1997;15:1611-1616.
38. Ramesh V: Aspects of tuberous sclerosis complex (TSC) protein function in the brain. Biochem Soc Trans 2003;31:579-583.
39. Onda H, Crino PB, Zhang H, et al: TSC2 null neuroepithelial cells are a model for human tuber giant cells and show activation of an mTOR pathway. Mol Cell Neurosci 2002;21:561-574.
40. Ito N, Rubin GM: gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 1999;96:529-539.
41. Potter CJ, Huang H, Xu T: Drosophila TSC1 functions with TSC2 to antagonize insulin signaling regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368.
42. Stocker H, Hafen E: Genetic control of cell size. Curr Opin Genet Dev 2000;10:529-535.
43. Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001;5:1383-1392.
44. Huang H, Potter CJ, Tao W, et al: PTEN affects cell size, cell proliferation, and apoptosis during Drosophila eye development. Development 1999;126:5365-5372.
45. Dan HC, Sun M, Yang L, et al: Phosphatidylinositol-3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002;277:35364-35370.
46. Inoki K, Li Y, Zhu T, et al: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002; 4:648-657.
47. Tee AR, Fingar DC, Manning BD, et al: Tuberous sclerosis complex-1 and 2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002;99:13571-13576.
48. Potter CJ, Pedraza LG, Xu T: Akt regulates growth by directly phosphorylating TSC2. Nat Cell Biol 2002;4:658-665.
49. Gao X, Zhang Y, Arrazola P, et al: Tsc tumor suppressor proteins antagonize amino acid-TOR signaling. Nat Cell Biol 2002;4:699-704.
50. Gingras A, Kennedy SG, O'Leary MA, et al: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998;12:502-513.
51. Fingar DC, Salama S, Tsou C, et al: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-1487.
52. Kwiatkowski DJ, Zhang H, Bandura JL, et al: A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas and upregulation of p70S6 kinase activity in TSC1 null cells. Hum Mol Genet 2002;11:525-534.
53. Garami A, Zwartkruis FJT, Nobukuni T, et al: Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003;11:1457-1466.
54. Castro AR, Rebhun JF, Clark GJ, Quilliam LA: Rheb binds TSC2 and promotes S6 kinase activation in a rapamycin and farnesylation-dependent manner. J Biol Chem 2003;278:32493-32496.
55. Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-1835.
56. Tabancay AP, Gau CL, Machado IMP, et al: Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem 2003;278:39921-39930.
57. Tee AR, Manning BD, Roux PP, et al: Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:1259-1268.
58. Zhang Y, Gao X, Saucedo LJ, et al: Rheb is a direct target of the tuberous sclerosis tumor suppressor proteins. Nat Cell Biol 2003;5:578-581.
59. Patel PH, Thapar N, Guo L, et al: Drosophila Rheb GTPase is required for cell cycle progression and growth control. J Cell Sci 2003;116:3601-3610.
60. Clark GJ, Kinch MS, Rogers-Graham K, et al: The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997;272:10608-10615.
61. Saucedo LJ, Gao X, Chiarelli DA, et al: Rheb promotes cell growth as a component of the insulin/TOR signaling network. Nat Cell Biol 2003;5:566-571.
62. Stocker H, Radimerski, Schindelholz B, et al: Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 2003;5:559-565.
63. +/- cells. Oneogene 2002;21:4050-4059.
64. Fero ML, Rivkin M, Tasch M, et al: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.
65. Yeung RS, Xiao GH, Jin F, et al: Predisposition to renal carcinoma in the Eker rat is determined by germline mutation of the tuberous sclerosis (TSC2) gene. Proc Natl Acad Sci U S A 1994;91: 11413-11416.
66. Yeung RS, Katsetos CD, Klein-Szanto A: Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am J Pathol 1997;151:1477-1486.
67. Jacob HJ, Kwitek AE: Rat genetics: Attaching physiology and pharmacology to the genome. Nat Rev Genet 2002;3:33-42.
68. Macleod KF, Jacks T: Insights into cancer from transgenic mouse models. J Pathol 1999;187:43-60.
69. Kobayashi T, Minowa O, Kuno J, et al: Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999;59: 1206-1211.
70. Kobayashi T, Minowa O, Sugitani Y, et al: A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 2001;98:8762-8767.
71. Dabora SL, Jozwiak S, Franz DN, et al: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80.
72. Uhlmann EJ, Wong M, Baldwin RL, et al: Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 2002;53:285-296.
73. Ess KC, Uhlmann EJ, Li W, et al: Expression profiling in tuberous sclerosis (TSC) knockout mouse astrocytes to characterize human TSC brain pathology. Glia 2004;46:28-40
74. Uhlmann EJ, Li W, Scheidenhelm D, et al: Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 2004;47:180-188.
75. Wong M, Ess KC, Uhlmann EJ, et al: Impaired astrocyte glutamate transport in a mouse epilepsy model of tuberous sclerosis. Ann Neurol 2003;54:251-256.
76. Bajenaru ML, Hernandez MR, Perry A, et al: Optic nerve glioma in mice requires Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003;63:8573-8577.
77. Haluska P, Dy GK, Adjei AA: Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002;38:1685-1700.